Mineralys Therapeutics, Inc. Enters into $100M ATM Equity Offering Sales Agreement

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, entered into an at-the-market (ATM) Equity Offering Sales Agreement with BofA Securities, Inc. and Evercore Group, LLC as sales agents and/or principals, and with Faegre Drinker serving as issuer’s counsel. Pursuant to the terms of the agreement, Mineralys Therapeutics, Inc. may sell from time to time through the agents up to $100 million of shares of its common stock pursuant to a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission. Mineralys Therapeutics, Inc. has raised over $100 million in 2024 alone and is currently advancing its initial product candidate, lorundrostat, in multiple clinical trials. This at-the-market program will allow Mineralys Therapeutics, Inc. to access the capital markets opportunistically over the coming years to continue funding its clinical trials and other operating expenses.